03 March 2022 | Thursday | News
Bioseet, based in Munich, Germany, is an enterprise encompassing a virtual marketplace and teamspace for Biosimilar and other generic assets to facilitate deals online. Being part of Bioseet will strengthen the company’s business development opportunities.
Paras Biopharmaceuticals biosimilar approach and portfolio pipeline comprises of unique biosimilars that have niche indications, low competition, high-value and growing market opportunity, and low risk for development.
The company’s product pipeline includes biosimilar candidates of Oncology, Osteoporosis, Rheumatoid Arthritis, and Metabolic Diseases. Paras Proprietary Technologies are used for scale-up optimization of Biosimilars with enhanced activity and greater stability. Paras Biopharmaceuticals looks forward to reaching out to global and regional pharma / biopharma companies for joint clinical development and high-value Biosimilars.
“Paras Biopharmaceuticals believes that its association with Bioseet will enable the company to reach out to selected and specific pharmaceutical partners to bring these high value and quality biologics at affordable prices,” says Dr Mark Jackson, Administration lead.
“Bioseet’s marketplace is the global leader in digital biosimilars deal initiation. The platform is tailor-made to the partnering needs of biosimilars and generics producers. Paras Biopharmaceuticals will benefit from the direct access to Bioseet’s growing network of commercialisation partners,“ says Olaf Ucksche, CEO of Bioseet.